Hanmi Pharmaceutical has entered into a supply agreement with Organon to export three combination medicines for the Malaysian and Philippine markets as part of the companies’ expansion efforts in Southeast Asia.

• Operational roles: Hanmi Pharmaceutical will supply the finished combination products, while Organon will oversee local marketing, distribution, and sales activities.
• Geographic coverage: The companies plan to pursue phased regulatory approvals and product launches in Malaysia and the Philippines.
• Therapeutic focus: The agreement covers combination therapies in the cardiovascular and respiratory therapeutic areas, including treatments for chronic conditions such as hypertension.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.